Rudd SG

Family name	Rudd
Given name	Sean G
Initials	SG
ORCID	ORCID 0000-0002-4368-3855
Affiliations	Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

20 publications

PubMed DOI Crossref

Repurposing Asparaginase Therapy to Target Cisplatin-Resistant Cancer Cells.

Wang J, Pouryaghoub N, Strauss R, ..., Zhang SM, Rudd SG

Fundam Clin Pharmacol 39 (5) e70044 [2025-10-00; online 2025-08-11]

DOI Crossref

Uridine cytidine kinases dictate the therapeutic response of molnupiravir via its bioactivation

Shu H, Sharm S, Alam S, ..., Rudd SG, Zhang SM

- - (-) - [2025-05-14; online 2025-05-14]

PubMed DOI Crossref

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.

Hormann FM, Rudd SG

Leukemia 39 (3) 531-542 [2025-03-00; online 2025-02-17]

PubMed DOI Crossref

Understanding the interplay between dNTP metabolism and genome stability in cancer.

Yagüe-Capilla M, Rudd SG

Dis Model Mech 17 (8) - [2024-08-01; online 2024-08-29]

DOI Crossref

Glutamine-addiction in cisplatin resistant cancer cells is mediated by SLC7A11 and can be targeted with asparaginase therapy

Wang J, Strauss R, Bartek J, Rudd SG

- - (-) - [2024-07-22; online 2024-07-22]

PubMed DOI Crossref

Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.

Rudd SG

Cancer Chemother. Pharmacol. 92 (4) 241-251 [2023-10-00; online 2023-07-15]

PubMed DOI Crossref

Targeting the DNA damage response and repair in cancer through nucleotide metabolism.

Helleday T, Rudd SG

Mol Oncol 16 (21) 3792-3810 [2022-11-00; online 2022-05-28]

PubMed DOI Crossref

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Ceder S, Eriksson SE, Liang YY, ..., Rudd SG, Wiman KG

Cell Death Dis 13 (8) 672 [2022-08-03; online 2022-08-03]

PubMed DOI Crossref

The prognostic and clinicopathological significance of desmoglein 2 in human cancers: a systematic review and meta-analysis.

Wang J, Hao S, Gu J, Rudd SG, Wang Y

PeerJ 10 (-) e13141 [2022-03-22; online 2022-03-22]

PubMed DOI Crossref

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Ceder S, Eriksson SE, Liang YY, ..., Rudd SG, Wiman KG

Cell Death Dis 12 (7) 709 [2021-07-15; online 2021-07-15]

PubMed DOI Crossref

Drug synergy scoring using minimal dose response matrices.

Mäkelä P, Zhang SM, Rudd SG

BMC Res Notes 14 (1) 27 [2021-01-19; online 2021-01-19]

DOI Crossref

Drug synergy scoring using minimal dose response matrices

Mäkelä P, Zhang SM, Rudd SG

- - (-) - [2020-10-31; online 2020-10-31]

PubMed DOI Crossref

MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.

Rudd SG, Gad H, Sanjiv K, ..., Berglund UW, Helleday T

Cancer Res. 80 (17) 3530-3541 [2020-09-01; online 2020-04-20]

DOI Crossref

SAMHD1 promotes oncogene-induced replication stress

Zhang SM, Calderón-Montaño JM, Rudd SG

- - (-) - [2020-07-29; online 2020-07-29]

PubMed DOI Crossref

Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Page BDG, Valerie NCK, Wright RHG, ..., Beato M, Helleday T

Nat Commun 10 (1) 5050 [2019-11-01; online 2019-11-01]

DOI Crossref

MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells

Gad H, Mortusewicz O, Rudd SG, ..., Berglund UW, Helleday T

- - (-) - [2019-03-12; online 2019-03-12]

DOI Crossref

MTH1 inhibitor TH588 induces mitosis-dependent accumulation of genomic 8-oxodG and disturbs mitotic progression

Rudd SG, Gad H, Amaral N, ..., Berglund UW, Helleday T

- - (-) - [2019-03-12; online 2019-03-12]

PubMed DOI Crossref

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, ..., Xagoraris I, Khoury JD

Blood Cancer J 8 (11) 98 [2018-10-19; online 2018-10-19]

PubMed DOI Crossref

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N

Cancers (Basel) 10 (7) - [2018-07-23; online 2018-07-23]

PubMed DOI Crossref

SAMHD1 is a barrier to antimetabolite-based cancer therapies.

Rudd SG, Schaller T, Herold N

Mol Cell Oncol 4 (2) e1287554 [2017-02-03; online 2017-02-03]